Day: September 6, 2022

Optimom 2M MIPI optical module Teledyne e2v’s Optimom 2M is a ready-to-use imaging solution that can be fine-tuned for any project with minimum developmentGRENOBLE, France, Sept. 06, 2022 (GLOBE NEWSWIRE) — Teledyne e2v announces the release of its 2-Megapixel Optimom™, the first in a range of MIPI CSI-2 optical modules. Powered by Teledyne e2v’s proprietary image sensor technology, Optimom has been thoughtfully designed to ensure there is minimum development effort required for vision-based embedded systems for robotics, logistics, drones, or laboratory equipment. Optimom™ 2M features a native MIPI CSI-2 protocol and standard FPC connector to link with embedded processing boards. Integration is instant using a dedicated Development Kit, which includes both an adapter board for hardware integration and Linux drivers for straightforward...

Company announcement no. 29     In company announcement no. 9 2022, Spar Nord announced a share buyback programme of up to DKK 225 million. The share buyback was initiated on 15 June 2022. The purpose of the share buyback is to reduce the bank’s share capital by the shares acquired under the programme, and the programme is executed pursuant to Regulation (EU) No 596/2014 of 16 April 2014 (“Market Abuse Regulation”). In week 35, the following transactions were made under the share buyback programme.  Number of shares Average purchase price Transaction value (DKK)Accumulated from last announcement 1,042,000     83,356,74229 August 2022  19,000  83.88  1,593,72030 August 2022  20,000  84.17  1,683,40031 August 2022  22,000  83.75  1,842,50001 September 2022  22,000  83.27  1,831,94002 September 2022  21,000  84.30  1,770,300Total...

Marimekko Corporation, Stock Exchange Release, 6 September 2022 at 7.46 a.m. Marimekko focuses on scaling its profitable growth during the next strategy period of 2023–2027 Marimekko intends to focus on scaling the Marimekko business and growth especially in international markets during the next strategy period of 2023–2027. The company will elaborate on the strategic direction and the new long-term financial goals published today in its Capital Markets Day on Wednesday, 14 September 2022. During the current strategy period of 2018–2022, Marimekko’s objective has been to achieve markedly stronger profitable growth than before by speaking to a broader target audience. The company’s net sales and profitability have developed strongly from year to year. Despite the challenging environment of the Coronavirus pandemic, 2021 was a record year...

Marimekko Corporation, Inside Information, 6 September 2022 at 7.45 a.m. Marimekko raises its long-term financial goals and focuses on scaling its profitable growth during the next strategy period Marimekko Board of Directors have decided on the new long-term financial goals for the company, raising the targets for net sales development and comparable operating profit margin. At the same time, the Board has set a direction for Marimekko’s next strategy period of 2023–2027, during which the company will focus on scaling the Marimekko business and growth especially in international markets, as described in a separate release. Marimekko will elaborate on the new long-term financial goals and strategic direction at the company’s first-ever Capital Markets Day on Wednesday, 14 September 2022. Marimekko’s long-term financial goals The new long-term...

Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022 NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) — Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testosterone deficiency...